Skip to content

Prognostic Value of Progesterone for In Vitro Fertilization (IVF) Outcome

The Effect of Serum Progesterone Levels on the Day of hCG Administration on the Probability of Pregnancy in Patients Treated by IVF Using GnRH Antagonists and Recombinant Gonadotrophins

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01067664
Acronym
PROG2
Enrollment
130
Registered
2010-02-11
Start date
2009-05-31
Completion date
2013-06-30
Last updated
2013-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subfertility

Brief summary

This observational study attempts to investigate the potential role of serum progesterone levels on the day of hCG administration (thus, the end of the follicular phase) on the probability of pregnancy, in patients undergoing IVF with the use of GnRH antagonists and recombinant gonadotrophins. There has been evidence, that increased serum levels of progesterone are associated with a decreased probability of pregnancy after IVF. This study will attempt to explore the role of progesterone on the outcome of IVF, by closely monitoring its levels during the late follicular phase.

Interventions

None listed

Sponsors

Aristotle University Of Thessaloniki
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 39 Years
Healthy volunteers
No

Inclusion criteria

* Age \< 40 years * Basal FSH \< 12 IU/L * Basal P \< 1.6 ng/mL

Exclusion criteria

* Presence of cystic formations at the ovaries during the basal ultrasound scan (prior the initiation of stimulation) * Women with polycystic ovaries syndrome (PCOS) * Women with Stage III-IV Endometriosis * Women with a pathological condition of the adrenal glands

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy, defined as ultrasound evidence of fetal heart activity at 6-8 weeks of gestationAt 6-8 weeks of gestation

Secondary

MeasureTime frame
Pregnancy (defined as a b-hCG> 25 IU/L)12 days after embryo transfer

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026